Fibrodysplasia Ossificans Progressiva: Developmental Implications of a Novel Metamorphogene

  • Frederick S. Kaplan
  • Jay C. Groppe
  • Petra Seemann
  • Robert J. Pignolo
  • Eileen M. Shore
Part of the Topics in Bone Biology book series (TBB, volume 6)


Robust developmental novelty often results from polymorphisms or mutations in the regulatory regions of genes that control major morphogenetic signaling pathways [77]. It is much more unusual for developmental novelty to arise from mutations in the protein-coding region of such genes, because they often lead to embryonic death or catastrophic postnatal phenotypes.


Heterotopic Ossification Heterotopic Bone Diarthrodial Joint Histidine Side Chain Cell Surface Heparan Sulfate Proteoglycan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Work by the authors discussed in this chapter was supported in part by the International Fibrodys­plasia Ossificans Progressiva Association, the Center for Research in FOP and Related Disorders, the Ian Cali Endowment for FOP Research, the Whitney Weldon Endowment for FOP Research, the Isaac & Rose Nassau Professorship of Orthopaedic Molecular Medicine, by grants from the Rita Allen Foundation and the US National Institutes of Health (NIH R01-AR41916).


  1. 1.
    Ahn J, Serrano de la Peña L, Shore EM, Kaplan FS (2003) Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg 85-A:667-674PubMedGoogle Scholar
  2. 2.
    Akiyama S, Katagiri T, Namiki M, Yamaji N, Yamamoto N, Miyama K, Shibuya H, Ueno N, Wozney JM, Suda T (1997) Constitutively active BMP type I receptors transduce BMP2 signals without the ligand in C2C12 myoblasts. Exp Cell Res 235:362-369PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson GJ, Darshan D (2008) Small-molecule dissection of BMP signaling. Nature Chem Biol 4: 15-16CrossRefGoogle Scholar
  4. 4.
    Barkai N, Shilo B-Z (2007) Variability and robustness in bimolecular systems. Mol Cell 28:755-760PubMedCrossRefGoogle Scholar
  5. 5.
    Billings PC, Fiori JL, Bentwood JL, O’Connell MP, Jiao X, Nussbaum B, Caron RJ, Shore EM, Kaplan FS (2008) Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva. J Bone Miner Res 23:305-313PubMedCrossRefGoogle Scholar
  6. 6.
    Birnbaum KD, Alvarado AS (2008) Slicing across kingdoms: regeneration in plants and animals. Cell 132:697-710PubMedCrossRefGoogle Scholar
  7. 7.
    Brunet LJ, McMahon JA, McMahon AP, Harland RM (1998) Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280:1455-1457PubMedCrossRefGoogle Scholar
  8. 8.
    Carlson BM (2005) Some principles of regeneration in mammalian systems. Anat Rec B New Anat 287B:4-13CrossRefGoogle Scholar
  9. 9.
    Chakkalakal SA, Zhang D, Raabe T, Richa J, Hankenson K, Kaplan FS, Shore EM (2008) ACVR1 knock-in mouse model for fibrodysplasia ossificans progressiva. J Bone Miner Res 23(suppl 1)Google Scholar
  10. 10.
    Chen Y-G, Liu F, Massague J (1997) Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J 16:3866-3876PubMedCrossRefGoogle Scholar
  11. 11.
    Cobaleda C, Jochum W, Busslinger M (2007) Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449:473-477PubMedCrossRefGoogle Scholar
  12. 12.
    Cohen RB, Hahn GV, Tabas J, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS (1993) The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg 75-A:215-219Google Scholar
  13. 13.
    Connor JM, Evans DA (1982) Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg 64(1):76-83Google Scholar
  14. 14.
    Cuny GD, Yui PB, Laha JK, Xing X, Liu J-F, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT (2008). Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 18(15):8366-8377CrossRefGoogle Scholar
  15. 15.
    Davis SR, Meltzer PS (2007) Modeling synovial sarcoma: timing is everything. Cancer Cell 11:305-307PubMedCrossRefGoogle Scholar
  16. 16.
    Deirmengian GK, Hebela NM, O’Connell M, Glaser DL, Shore EM, Kaplan FS, Deirmengian GK (2008) Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 90:366-374PubMedCrossRefGoogle Scholar
  17. 17.
    De Robertis EM (2008) Evo-Devo: variations on ancestral themes. Cell 132:185-195PubMedCrossRefGoogle Scholar
  18. 18.
    Derynck R, Akhurst RJ (2007) Differentiation plasticity regulated by the TGF-β family proteins in development and disease. Nature Cell Biol 9:1000-1004PubMedCrossRefGoogle Scholar
  19. 19.
    Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K (2001) Smurf 1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477-12480PubMedCrossRefGoogle Scholar
  20. 20.
    Everman DB, Bartels CF, Yang Y, Yanamandra N, Goodman FR, Mendoza-Londono JR, Savarirayan R, White SM, Graham JM Jr, Gale RP, Svarch E, Newman WG, Kleckers AR, Francomano CA, Govindaiah V, Singh L, Morrison S, Thomas JT, Warman ML (2002) The mutational spectrum of brachydactyly type C. Am J Med Genet 112(3):291-296PubMedCrossRefGoogle Scholar
  21. 21.
    Fiori JL, Billings PC, Serrano de la Peña L, Kaplan FS, Shore EM (2006) Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 21:902-909PubMedCrossRefGoogle Scholar
  22. 22.
    Fishman MC, Porter JA (2005) A new grammar for drug discovery. Nature 437:491-493PubMedCrossRefGoogle Scholar
  23. 23.
    Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis EM (2007) Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/SMAD1 signal. Cell 131:980-993PubMedCrossRefGoogle Scholar
  24. 24.
    Fukada T, Kohda M, Kanomata K, Nojima J, Kamizono J, Oda H, Nakayama K, Ohtake A, Miyazono K, Jimi E, Owan I, Okazaki Y, Katagiri T (2007) A constitutively activated BMP receptor, ALK2, induces heterotopic ossification in patients with fibrodysplasia ossificans progressiva. J Bone Miner Res 22(suppl 1):S10Google Scholar
  25. 25.
    Gannon FH, Kaplan FS, Olmsted E, Finkel G, Zasloff MA, Shore EM (1997) Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol 28:339-343PubMedCrossRefGoogle Scholar
  26. 26.
    Gannon FH, Valentine BA, Shore EM, Zasloff MA, Kaplan FS (1998) Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 346:19-25Google Scholar
  27. 27.
    Glaser DL, Economides AN, Wang L, Liu X, Kimble RD, Fandl JP, Wilson JM, Stahl N, Kaplan FS, Shore EM (2003) In vivo somatic cell gene transfer of an ­engineered noggin mutein prevents BMP4-induced ­heterotopic ossification. J Bone Joint Surg 85-A:2332-2342PubMedGoogle Scholar
  28. 28.
    Glaser DL, Rocke DM, Kaplan FS (1998) Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 346:110-116Google Scholar
  29. 29.
    Groppe JC, Shore EM, Kaplan FS (2007) Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Rel Res 462:87-92CrossRefGoogle Scholar
  30. 30.
    Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11:375-388PubMedCrossRefGoogle Scholar
  31. 31.
    Harradine KA, Akhurst RJ (2006) Mutations of TGF-β signaling molecules in human disease. Ann Med 38:403-414PubMedCrossRefGoogle Scholar
  32. 32.
    Hartung A, Sieber C, Knaus P (2006) Yin and Yang in BMP signaling: impact on the pathology of diseases and potential for tissue regeneration. Signal Transduct 6:314-328CrossRefGoogle Scholar
  33. 33.
    Hebela N, Shore EM, Kaplan FS (2005) Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. Clin Rev Bone Miner Metab 3:205-208CrossRefGoogle Scholar
  34. 34.
    Hegyi L, Gannon FH, Glaser DL, Shore EM, Kaplan FS, Shanahan CM (2003) Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. J Pathol 201:141-148PubMedCrossRefGoogle Scholar
  35. 35.
    Herpin A, Cunningham C (2007) Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J 274:2977-2985PubMedCrossRefGoogle Scholar
  36. 36.
    Huse M, Chen Y-G, Massague J, Kuriyan J (1999) Crystal structure of the cytosplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell 96:425-436PubMedCrossRefGoogle Scholar
  37. 37.
    Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J (2001) The TGF-β receptor activation process: an inhibitor-to-substrate binding switch. Mol Cell 8:671-682PubMedCrossRefGoogle Scholar
  38. 38.
    Ingber DE, Levin M (2007) What lies at the interface of regenerative medicine and developmental biology? Development 134:2541-2547PubMedCrossRefGoogle Scholar
  39. 39.
    Janoff HB, Zasloff MA, Kaplan FS (1996) Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg 114:599-604PubMedCrossRefGoogle Scholar
  40. 40.
    Jiao X, Billings PC, O’Connell MP, Kaplan FS, Shore EM, Glaser DL (2007) Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 282(2):1080-1086PubMedCrossRefGoogle Scholar
  41. 41.
    Kan L, Hu M, Gomes WA, Kessler JA (2004) Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol 165:1107-1115PubMedGoogle Scholar
  42. 42.
    Kan L, Liu Y, McGuire TL, Berger DMP, Atwatramani RB, Dymecki SM, Kessler JA (2009) Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells, 27:150-156PubMedCrossRefGoogle Scholar
  43. 43.
    Kaplan FS (2005) Fibrodysplasia ossificans progressiva: an historical perspective. Clin Rev Bone Miner Metab 3:179-181CrossRefGoogle Scholar
  44. 44.
    Kaplan FS (2006) The key to the closet is the key to the kingdom: a common lesson of rare diseases. Orphan Dis Update 24(3):1-9Google Scholar
  45. 45.
    Kaplan FS, Fiori JL, Ahn J, Billings PC, Shore EM (2005) Dysregulation of BMP4 receptor trafficking and signaling in fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:217-223CrossRefGoogle Scholar
  46. 46.
    Kaplan FS, Fiori J, Serrano de la Peña L, Ahn J, Billings PC, Shore EM (2006) Dysregulation of the BMP4 signaling pathway in fibrodysplasia ossificans progressiva. Ann N Y Acad Sci 1068:54-65PubMedCrossRefGoogle Scholar
  47. 47.
    Kaplan FS, Glaser DL (2005) Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:213-216CrossRefGoogle Scholar
  48. 48.
    Kaplan FS, Glaser DL, Pignolo RJ, Shore EM (2004) A new era of fibrodysplasia ossificans progressiva (FOP): a druggable target for the second skeleton. Exp Opin Biol Ther 7:705-712CrossRefGoogle Scholar
  49. 49.
    Kaplan FS, Glaser DL, Shore EM, Deirmengian GK, Gupta R, Delai P, Morhart P, Smith R, Le Merrer M, Rogers JG, Connor JM, Kitterman JA (2005) The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:183-188CrossRefGoogle Scholar
  50. 50.
    Kaplan FS, Glaser DL, Shore EM, Pignolo RJ, Xu M, Zhang Y, Senitzer D, Forman SJ, Emerson SG (2007) Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am 89:347-357PubMedCrossRefGoogle Scholar
  51. 51.
    Kaplan FS, Hahn GV, Zasloff MA (2004) Heterotopic ossification. J Am Acad Orthop Surg 12:116-125PubMedGoogle Scholar
  52. 52.
    Kaplan FS, LeMerrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM (2008) Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22:191-205PubMedCrossRefGoogle Scholar
  53. 53.
    Kaplan FS, Shore EM (2007) Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis. Ann N Y Acad Sci 1116:113-133PubMedCrossRefGoogle Scholar
  54. 54.
    Kaplan FS, Shore EM, Gupta R, Billings PC, Glaser DL, Pignolo RJ, Graf D, Kamoun M (2005) Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 Pathway. Clin Rev Bone Miner Metab 3:189-193CrossRefGoogle Scholar
  55. 55.
    Kaplan FS, Strear CM, Zasloff MA (1994) Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 304:238-247Google Scholar
  56. 56.
    Kaplan FS, Tabas JA, Zasloff MA (1990) Fibrodysplasia ossificans progressiva: a clue from the fly? Calcif Tiss Int 47:117-125CrossRefGoogle Scholar
  57. 57.
    Kaplan FS, Xu M, Glaser DL Collins F, Connor M, Kitterman J, Sillence D, Zackai E, Ravitsky V, Zasloff M, Ganguly A, Shore EM (2008) Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 121: e1295-e1300PubMedCrossRefGoogle Scholar
  58. 58.
    Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll, L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi S-A, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM (2008) Classic and atypical FOP phenotypes caused by mutations in the BMP type I receptor ACVR1. Hum Mutat 30:379-390CrossRefGoogle Scholar
  59. 59.
    Kaplan FS, Zasloff MA (1993) The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J Bone Joint Surg 75-A:220-230Google Scholar
  60. 60.
    Kitterman JA, Kantanie S, Rocke DM, Kaplan FS (2005) Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116: 654-661CrossRefGoogle Scholar
  61. 61.
    Koentges G (2008) Evolution of anatomy and gene control. Nature 451:658-663PubMedCrossRefGoogle Scholar
  62. 62.
    Kussmaul WG, Esmail AN, Sagar Y, Ross J, Gregory S, Kaplan FS (1998) Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 346:104-109Google Scholar
  63. 63.
    Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS (1995) Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr 126:762-764PubMedCrossRefGoogle Scholar
  64. 64.
    Lander AD (2007) Morpheus unbound: reimagining the morphogen gradient. Cell 128:245-256PubMedCrossRefGoogle Scholar
  65. 65.
    Lehmann K, Seemann P, Boergermann J, Morin G, Reif S, Knaus P, Mundlos S (2006) A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type C/symphalangism-like phenotype or brachydactyly type A2. Eur J Hum Genet 14(12):1248-54PubMedCrossRefGoogle Scholar
  66. 66.
    Lehmann K, Seemann P, Stricker S, Sammar M, Meyer B, Süring K, Majewski F, Tinschert S, Grzeschik K-H, Müller D, Knaus, P, Nürnberg P, Mundlos S (2003) Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2. Proc Natl Acad Sci U S A 100(21):12277-82PubMedCrossRefGoogle Scholar
  67. 67.
    Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment ADA, Shore EM, Glaser EM, Goldhamer DJ, Kaplan FS (2008) Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surgery Am 91:652-663CrossRefGoogle Scholar
  68. 68.
    Luchetti W, Cohen RB, Hahn GV, Rocke DM, Helpin M, Zasloff M, Kaplan FS (1995) Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:21-25CrossRefGoogle Scholar
  69. 69.
    Mahboubi S, Glaser DL, Shore EM, Kaplan FS (2001) Fibrodysplasia ossificans progressiva. Pediatr Radiol 31:307-314PubMedCrossRefGoogle Scholar
  70. 70.
    Mishina Y, Crombie R, Bradley A, Behringer RR (1999) Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. Dev Biol 213(2):314-26PubMedCrossRefGoogle Scholar
  71. 71.
    Moriatis JM, Gannon FH, Shore EM, Bilker W, Zasloff MA, Kaplan FS (1997) Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 336:247-253CrossRefGoogle Scholar
  72. 72.
    Olmsted EA, Kaplan FS, Shore EM (2003) Bone morphogenetic protein 4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 408: 331-343CrossRefGoogle Scholar
  73. 73.
    Olmsted-Davis E, Gannon FH, Ozen M, Ittmann MM, Gugala Z, Hipp JA, Moran KM, Fouletier-Dilling CM, Schumara-Martin S, Lindsey RW, Heggeness MH, Brenner MK, Davis AR (2007) Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol 170:620-632PubMedCrossRefGoogle Scholar
  74. 74.
    Ovchinnikov DA, Selever J, Ying W, Chen Y-T, Mishina Y, Martin JF, Behringer RR (2006) BMP receptor type IA in limb bud mesenchyme regulates distal outgrowth and patterning. Dev Biol 295(1):10-3-15CrossRefGoogle Scholar
  75. 75.
    Pignolo RJ, Suda RK, Kaplan FS (2005) The fibrodysplasia ossificans progressiva lesion. Clin Rev Bone Miner Metab 3:195-200CrossRefGoogle Scholar
  76. 76.
    Plöger F, Seemann P, Schmidt-von Kegler M, Lehmann K, Seidel J, Kjaer KW, Pohl J, Mundlos S (2008) Brachydactyly type A2 associated with a defect in proGDF5 BMP processing. Hum Mol Genet 17(9):1222-1233PubMedCrossRefGoogle Scholar
  77. 77.
    Prud’homme B, Gompel N, Carroll SB (2007) Emerging principles of regulatory evolution. Proc Natl Acad Sci U S A 104(suppl 1):8605-8612PubMedCrossRefGoogle Scholar
  78. 78.
    Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS (1994) Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Rel Res 301:243-248Google Scholar
  79. 79.
    Rosenstirn JA (1918) A contribution to the study of myositis ossificans progressiva. Ann Surg 68:468-520; 591-637CrossRefGoogle Scholar
  80. 80.
    Roush W (1996) Protein builds second skeleton. Science 273:1170PubMedCrossRefGoogle Scholar
  81. 81.
    Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS (2004). Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP) Clin Orthop Rel Res 423:275-279CrossRefGoogle Scholar
  82. 82.
    Schaffer AA, Kaplan FS, Tracy MR, O’Brien ML, Dormans JP, Shore EM, Harland RM, Kusumi K (2005) Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 30:1379-1385PubMedCrossRefGoogle Scholar
  83. 83.
    Schmierer B, Hill CS (2007) TGF-β-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Bio 8:970-982CrossRefGoogle Scholar
  84. 84.
    Seemann P, Schwappacher R, Kjaer KW, Krakow D, Lehmann K, Dawson K, Stricker S, Pohl J, Plöger F, Staub E, Nickel J, Sebald W, Knaus P, Mundlos S (2005) Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest 115(9):2373-81PubMedCrossRefGoogle Scholar
  85. 85.
    Serrano de la Peña L, Billings PC, Fiori JL, Ahn J, Shore EM, Kaplan FS (2005) Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 20:1168-1176CrossRefGoogle Scholar
  86. 86.
    Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS (1996) Over-expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561PubMedCrossRefGoogle Scholar
  87. 87.
    Shah PB, Zasloff MA, Drummond D, Kaplan FS (1994) Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg 76-A:1442-1450Google Scholar
  88. 88.
    Shen Q, Xu M, Little SC, Kaplan FS, Mullins MC, Shore EM (2007) Activation of BMP signaling by the FOP ACVR1 R206H mutation. J Bone Miner Res 22(suppl 1):S43Google Scholar
  89. 89.
    Shore EM, Feldman GJ, Xu M, Kaplan FS (2005) The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:201-204CrossRefGoogle Scholar
  90. 90.
    Shore EM, Kaplan FS (2008) Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 43:427-433PubMedCrossRefGoogle Scholar
  91. 91.
    Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, Le Merrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525-527PubMedCrossRefGoogle Scholar
  92. 92.
    Stoick-Cooper CL, Moon RT, Weidinger G (2007) Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes Dev 21:1292-1315PubMedCrossRefGoogle Scholar
  93. 93.
    Verheyen EM (2007) Opposing effects of Wnt and MAPK on BMP/SMAD signal duration. Dev Cell 13:755-756PubMedCrossRefGoogle Scholar
  94. 94.
    Wagner TU (2007) Bone morphogenetic protein signaling in stem cells - one signal many consequences. FEBS J 274:2968-2976PubMedCrossRefGoogle Scholar
  95. 95.
    Wang T, Li B-Y, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK (1996) The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell 86:435-444PubMedCrossRefGoogle Scholar
  96. 96.
    Xu MQ, Feldman G, LeMerrer M, Shugart YY, Glaser DL, Urtizberea JA, Fardeau M, Connor JM, Triffitt J, Smith R, Shore EM, Kaplan FS (2000) Linkage exclusion and mutational analysis of the noggin gene in patients with fibrodysplasia ossificans progressiva (FOP). Clin Genet 58:291-298PubMedCrossRefGoogle Scholar
  97. 97.
    Yamaguchi T, Kurisaki A, Yamakawa N, Minakuchi K, Sugino H (2006) FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. J Mol Endocrinol 36:569-579PubMedCrossRefGoogle Scholar
  98. 98.
    Yi SE, Daluiski A, Pederson R, Rosen V, Lyons KM (2000) The type I BMP receptor BMPR1B is required for chondrogenesis in the mouse limb. Development 127(3):621-30PubMedGoogle Scholar
  99. 99.
    Yoon BS, Lyons KM (2004) Multiple functions of BMPs in chondrogenesis. J Cell Biochem 93(1):93-103PubMedCrossRefGoogle Scholar
  100. 100.
    Yoon BS, Ovchinnikov DA, Yoshii I, Mishina Y, Behringer RR, Lyons KM (2005) BMPR1A and BMPR1B have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci U S A 102(14):5062-7PubMedCrossRefGoogle Scholar
  101. 101.
    Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD (2008) BMP type I receptor inhibition prevents ectopic ossification in mouse model of fibrodysplasia ossificans progressiva (FOP). Nat Med 14(12):1363-1364PubMedCrossRefGoogle Scholar
  102. 102.
    Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Block KD, Peterson RT (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4:33-41PubMedCrossRefGoogle Scholar
  103. 103.
    Zhang D, Schwarz EM, Rosier RN, Zuscik MJ, Puzas JE, O’Keefe RJ (2003) ALK2 functions as a BMP type I receptor and induces Indian Hedgehog in chondrocytes during skeletal development. J Bone Miner Res 18:1593-1604PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2010

Authors and Affiliations

  • Frederick S. Kaplan
    • 1
  • Jay C. Groppe
    • 2
  • Petra Seemann
    • 3
  • Robert J. Pignolo
    • 4
  • Eileen M. Shore
    • 5
  1. 1.Division of Molecular Orthopaedic Medicine Department of Orthopaedic SurgeryThe University of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.Department of Biomedical Sciences Baylor College of DentistryTexas A&M University Health Science CenterDallasUSA
  3. 3.Berlin-Brandenburg Center for Regenerative TherapiesInstitution Charité Universitätsmedizin BerlinBerlinGER
  4. 4.Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  5. 5.Department of Orthopaedic SurgeryUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations